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Purpose: To identify candidate protein biomarkers in sera indicative of acute retinal injury.
Methods: We used laser photocoagulation as a model of acute retinal injury in Rhesus macaques. In a paired-control
study design, we collected serum from each animal (n=6) at 4 h, 1 day, and 3 days following a mock procedure and then
again following retinal laser treatment that produced mild lesions. Samples were fractionated by isoelectric focusing,
digested with trypsin, and analyzed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Spectral counting
was used to determine relative protein abundances and identify proteins with statistically significant differences between
control and treated sera.
Results: Mild retinal injury was confirmed by fundus photography and histological examination. The average number of
total proteins detected by LC-MS/MS was 908±82 among samples from all three time points. Following statistical analysis
and employing stringent filtering criteria, a total of 19 proteins were identified as being significantly more abundant in
sera following laser-induced retinal injury, relative to control sera. Many of the proteins detected were unique to one time
point. However, four proteins (phosphoglycerate kinase 1, keratin 18, Lewis alpha-3-fucosyltransferase, and ephrin
receptor A2) showed differences that were significant at both 4 h and 1 day after laser treatment, followed by a decrease
to baseline levels by day 3.
Conclusions: A serum biomarker response to mild retinal laser injury was demonstrated in a primate model. Among the
proteins detected with highest significant differences, most are upregulated within 24 h, and their appearance in the serum
is transient. It is conceivable that a panel of these proteins could provide a means for detecting the acute-phase response
to retinal injury. Further investigation of these candidate biomarkers and their correlation to retinal damage is warranted.
Retinal proteins have been found in the serum of patients
with  conditions  such  as  retinal  detachment  and  diabetic
retinopathy [1,2]. However, the identification of acute-phase
biomarkers following retinal injury has not been described.
We hypothesized that retinal injury by laser photocoagulation
causes  death  and/or  injury  of  photoreceptor  and  retinal
pigment epithelium (RPE) cells, and that proteins that may be
upregulated in response to the damage will be released from
those,  or  adjacent,  cells  into  the  systemic  circulation.
Detection  of  such  proteins  in  serum  would  allow  the
identification  of  candidate  biomarkers.  A  panel  of  serum
biomarkers could provide the basis for the development of a
rapid and minimally invasive diagnostic test to detect acute
retinal injury.
Laser-induced retinal damage for energy levels above the
clinically  detectable  threshold  has  been  well  described.
Retinal damage can be localized to deep or superficial layers,
or might involve the entire retinal thickness, and has been
extensively studied in animal models [3-5]. The mechanism
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of  damage  may  be  photothermal,  photomechanical,
photodisruptive,  or  photochemical  [3].  Irrespective  of  the
mechanism of damage, laser-tissue reaction leads to varying
degrees of retinal neuronal and RPE cell damage or death
[3-7]. It also leads to altered protein expression in the retina
and disruption of the outer blood-retinal barrier [8-12]. It is
conceivable that such events would lead to the leakage of
proteins from the damaged photoreceptor/RPE cells and/or
surrounding tissue through the underlying choroid and into
the systemic circulation.
We sought to discover whether retinal injury could cause
detectable leakage of proteins from the retina into the systemic
circulation. Using a proteomics approach, we investigated
whether detection of this acute-phase response process was
possible over a three day course of time following injury.
Liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis of complex biologic fluids is a highly sensitive
method for observing qualitative and quantitative changes in
protein  content.  Others  have  used  LC-MS/MS-based
proteomics as a means of detecting changes due to ocular
disease  [2,13]  and  the  technique  is  used  extensively  for
biomarker discovery. We used laser photocoagulation as a
model  of  acute  retinal  damage  in  non-human  primates
Molecular Vision 2011; 17:779-791 <http://www.molvis.org/molvis/v17/a88>
Received 14 October 2010 | Accepted 18 March 2011 | Published 23 March 2011
© 2011 Molecular Vision
779followed by LC-MS/MS analysis to identify candidate protein
biomarkers of retinal injury in serum.
METHODS
Animals: Seven female Rhesus macaques (Macaca mulatta),
aged 2.5–3.5 years and weighing 3.0–4.5 kg, were used in this
study. One animal was used for clinicopathologic correlation
of laser injury and the remaining six were treated in a paired-
control fashion. This study was conducted in accordance with
the Association for Research in Vision and Ophthalmology’s
Statement for the Use of Animals in Ophthalmic and Vision
Research, and all experimental procedures were approved by
the  Institutional  Animal  Care  and  Use  Committee  at
Northeastern  Ohio  Universities  Colleges  of  Medicine  and
Pharmacy.
All  animal  procedures  were  performed  under  general
anesthesia  using  10  mg/kg  ketamine  and  0.075  mg/kg
medetomidine, delivered intramuscularly. Upon completion
of the procedures, 0.075 mg/kg atipamezole was administered
as a reversing agent.
Laser treatment: We studied the serum biomarker response
from retinal laser lesions ranging from mild to minimally
visible lesions (MVLs). These retinal laser lesions appeared
light gray to yellow in color immediately after the injury. It
has been reported that these MVLs are not visible one week
after laser exposure [3,5,7,14]. In one animal, we tested the
ability to create MVLs that could be confirmed clinically and
upon pathologic examination. Higher intensity laser burns
were  created  as  rows  parallel  to  MVLs  to  aid  in  their
identification  upon  clinical  and  pathologic  examination.
Fundus  images  were  taken  immediately  following  laser
treatment.  The  eye  was  enucleated  24  h  later,  following
euthanasia, for histological examination. The whole globe
was fixed in 10% neutral buffered formalin, after which the
retinal area containing lesions was carefully dissected and
oriented to ensure both lesion types could be observed in the
sections. The tissue was processed, embedded in paraffin,
sectioned,  and  stained  with  hematoxylin  and  eosin.  The
experimental mock control and MVL procedures were then
performed, as described below.
Each animal in this experiment served as its own control
by undergoing a pre-treatment mock procedure. In this way,
a baseline serum proteome was established for each animal,
allowing  any  changes  that  may  have  occurred  due  to
anesthesia,  pupil  dilation,  or  handling  to  be  excluded.
Following general anesthesia, the pupils were dilated with one
drop each of tropicamide 1.0% (Bausch & Lomb, Tampa, FL)
and  phenylephrine  HCl  2.5%  (Alcon  Laboratories,  Fort
Worth, TX), and one drop of proparacaine HCl 0.5% (Bausch
&  Lomb)  was  instilled  as  a  local  anesthetic.  Eyes  were
examined by indirect ophthalmoscopy to rule out the presence
of  any  retinal  abnormality  or  other  ocular  disease.  Three
weeks following the control experiment, the animals were
treated in a similar fashion, except that the right eye of each
animal received laser treatment. Laser photocoagulation was
performed with a frequency-doubled Nd: YAG 532 nm laser
(OcuLight®GL; IRIDEX Corporation, Mountain View, CA).
A total of 15 laser spots were applied to the retina superior to
the optic nerve in the right eye. The laser settings were 500 µm
spot  diameter,  130–160  mW  power  intensity,  and  0.1  s
duration. These parameters consistently produced MVLs, as
described previously.
Sample  collection:  Blood  was  collected  by  venipuncture,
under general anesthesia, at 4 h, 1 day, and 3 days following
both the mock procedure and the laser treatment. At each time
point, approximately 5 ml of blood was drawn into collection
tubes free of clot activator or other additives. After clotting at
room temperature, the blood was centrifuged at 2,500× g for
10  min  for  serum  separation.  The  collected  serum  was
aliquoted to 1.5 ml tubes and stored at −80 °C until used for
proteomic analysis.
Sample preparation and mass spectrometry: Knowing that
protein  concentrations  in  serum  span  a  dynamic  range  of
greater than 10 orders of magnitude [15,16] and that the 6–10
highest abundance serum proteins, which include albumin and
globulin, account for greater than 90% of the total protein
content  [17,18],  it  is  imperative  to  employ  sample  pre-
fractionation before conducting mass spectrometry.
Albumin and globulin depletion is one way to reduce the
complexity of serum, but may also lead to the depletion of
potentially important protein targets and non-specific loss of
low abundance proteins [19,20]. We elected to reduce the
complexity  of  the  serum  by  subjecting  it  to  isoelectric
focusing (IEF), which does not involve the removal of any
proteins.  This  process,  when  compared  to  that  without
fractionation, led to the identification of six times the number
of proteins using mass spectrometry. The use of IEF increased
both the protein detection and identification rates to a degree
that  helped  determine  differences  between  the  serum
proteomes of control and treated animals.
The  serum  samples  were  pre-fractionated  offline  by
liquid-phase  IEF  using  a  MicroRotofor™  (Bio-Rad
Laboratories, Hercules, CA). Fifty microliters of each sample
were focused in the range between pH 3–10, producing ten
fractions that were each collected in a final volume of 200 µl.
One  hundred  microliters  from  each  serum  fraction  was
processed as described by Yu et al. [21], with minor changes
to  the  wash  steps,  as  follows.  In  brief,  gel  pieces  were
incubated with 40% methanol + 7% acetic acid for 30 min,
washed  four  times  in  water  for  30  min  under  sonication,
washed once in 200 mM ammonium bicarbonate (pH 8) and
twice in 50% acetonitrile, 100 mM ammonium bicarbonate
(pH 8). Following drying of the gel pieces, each was incubated
overnight  at  37  °C  in  a  solution  of  100  mM  ammonium
bicarbonate  (pH  8)  containing  0.5  µg  trypsin  (Promega
Corporation, Madison, WI). Peptides were extracted twice
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780from the gel pieces using 70% acetonitrile and 0.1% formic
acid and then dried. Extracts were resuspended in 20 µl of 6
M guanidine-HCl, 5 mM potassium phosphate, and 1 mM
DTT (pH 6.5), sonicated, and passed through a C18 ZipTip
(Millipore, Billerica, MA) to extract the peptides, which were
then  dried.  Prior  to  mass  spectrometry,  the  dried  peptide
extracts were dissolved in 5 µl of 5% acetonitrile and 0.1%
formic acid.
Peptides from each IEF fraction were analyzed once by
automated nano-flow liquid chromatography tandem mass
spectrometry (nano-flow LC-MS/MS) using an LTQ linear
ion  trap  mass  spectrometer  (Thermo  Fisher  Scientific,
Waltham, MA), coupled to a Surveyor HPLC system (Thermo
Fisher  Scientific)  equipped  with  a  Finnigan  Micro  AS
autosampler, and interfaced with an Aquasil C18 PicoFrit
75 µm×10 cm capillary column (New Objective, Woburn,
MA). Peptide mixtures were first separated using the C18
reverse phase column (1 µl/min flow rate) in line with the mass
spectrometer. Mobile phases consisted of 0.1% formic acid,
5% acetonitrile and 0.1% formic acid with 95% acetonitrile
for solvents A and B, respectively. A linear gradient of 180
min was followed by 60 min equilibration in solvent A. Ions
eluted from the column were electrosprayed at a voltage of
1.75 kV. The LC-MS/MS cycle was 6 MS/MS scans per full
MS scan. Dynamic exclusion enabled ±1.5 Da tolerance and
12 s exclusion duration.
Data  analysis:  Data  generated  from  the  raw  spectra  was
searched against the Macaca mulatta subset of the UniProt
database using the Sequest (V.12) program using a peptide
mass tolerance of 2.5 Da, a fragment mass tolerance of “0”
(which is effectively 1 Da), and monoisotopic masses.
Probability  scores  were  calculated  using  Epitomize
software [22,23] (Medical College of Wisconsin, Milwaukee,
WI) and filtered at 0.85 and 0.60 for spectra and protein hits,
respectively. Additionally, proteins identified by less than two
unique  peptides  were  eliminated  and  not  considered  for
further statistical analysis. The protein hits from each set of
ten IEF fractions for each sample were combined to represent
the serum proteome of that specimen at the given time point.
For each time point, the data results from all control and
treated  specimens  were  quantitatively  compared  using
Visualize software [22,23] (Medical College of Wisconsin,
Milwaukee, WI). A normalized p value for each protein was
calculated using the G test as previously described [24]. These
results were compiled into full and un-edited lists of proteins,
before application of any further statistical criteria or filtering,
and are available as supplemental data in Appendix 1, as
described  below  in  the  Results  section.  Proteins  with  a
normalized  p  value  <0.05  were  filtered  to  identify  those
detected  either  in  treated  samples  only  or  with  increased
abundance in treated samples relative to the controls. The p
values for this subset of data were adjusted according to the
Holm-Sidak method of correction for multiple comparisons.
Proteins  with  an  adjusted  p  value  <0.05  were  considered
significant and were retained. Proteins were eliminated from
the list if the normalized scan count ratio did not represent at
least a twofold increase in the treated group relative to the
control.  Additionally,  proteins  were  filtered  based  on  the
frequency of detection; they were not included in the final list,
despite their statistical significance, unless detected in at least
50% of the treated samples. The stringent statistical criteria
and sorting methods were chosen to increase confidence in the
final panel of candidate protein biomarkers. These choices
helped to eliminate proteins that may have been specific only
to individual animals or that may have been unrelated to the
injury. Using our method, we minimized the rate of false
identification and compiled a list of proteins that were both
significantly present in each sample and significantly different
between treatment groups. These methods for the comparative
analysis of proteomic data sets have been successfully used in
our laboratory, as described in a recent publication [25].
Protein lists for each time point were analyzed using
Pathway Studio software (Ariadne, Rockville, MD). Using the
human homolog gene identifiers, each protein was mapped to
its associated gene ontology (GO) terms for both cellular
components and biologic processes. The GO terms for each
category were analyzed for enrichment. Terms common to the
greatest number of proteins were used as the defining terms
in each category.
RESULTS
Histopathological assessment of laser lesions: We confirmed
the ability to create MVLs and mild type laser lesions, as
demonstrated  by  fundus  photography  and  histological
examination. The pathologic changes associated with MVLs
or severe type lesions were distinct and clearly identifiable in
histological sections of treated retinas at 1 day after laser
injury and when compared to normal retinas (Figure 1).
Protein identification and normalized scan count ratio: The
total number of proteins detected by LC-MS/MS analysis
were 818, 928, and 978 at the 4 h, 1 day, and 3 days time
points, respectively. A comprehensive list of these proteins,
identified by two or more non-redundant peptides, appears in
Appendix  1  as  supplemental  data.  These  protein
identifications served as the starting point for determining a
final list of candidate biomarkers. For biomarkers of retinal
injury, we chose to consider only those proteins that were
either present in treated samples only or that showed increased
abundance in treated samples relative to controls. In this case,
the  numbers  of  proteins  considered  for  further  statistical
analysis and data filtering were 259, 189, and 353 for the 4 h,
1 day, and 3 days time points, respectively. The numbers of
proteins that passed the additional statistical testing and met
the final filtering criteria were 8, 12, and 3 for the 4 h, 1 day,
and 3 days time points, respectively (Table 1). Based on their
normalized scan count ratios, these proteins were identified
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781as being considerably more abundant in sera following laser
treatment.
Sera from the 4 h and 1 day time points had four proteins
in common that were detected at significantly higher levels in
treated samples compared to mock samples (Figure 2). These
included  phosphoglycerate  kinase  1  (PGK1),  keratin  18
(CK18),  Lewis  alpha-3-fucosyltransferase  (FUT3),  and
ephrin receptor A2 (EPHA2). Additionally, these proteins
showed  high  reproducibility  for  detection,  having  been
identified in all six treated samples at both time points.
Six proteins were detected in either the 4 h or 1 day sera
of treated animals only. In all cases, these proteins were also
detected in both control and treated samples at the other time
points, but the differences were not significant.
Gene  ontology:  The  19  proteins  identified  by  spectral
counting as potential biomarkers were classified according to
gene ontology (GO) terms for both cellular components and
Figure 1. Fundus examination and histological evaluation of severe and MVL type laser lesions in a retina. A: Rows of severe lesions (arrows)
and MVL (arrow heads) caught by fundus imaging immediately following laser treatment. B-D: Histology of normal and laser-treated retina
1 day following laser injury. B: Normal retina adjacent to the region that was treated with laser. Note the intact sensory retina and retinal
pigment epithelium. C: Minimally visible lesions show mild swelling of the outer nuclear layer (line), condensation of cone inner segments
(arrow), and mild disruption of photoreceptor outer segments (*) and RPE. The inner retina and underlying choroid are unaffected. D: A severe
retinal lesion showing outer retinal swelling with disruption of the outer nuclear layer, the outer plexiform layer, and portions of the inner
nuclear layer (line). Note the mummification of photoreceptor inner segments (*), as indicated by shrinkage and condensation (arrow). Also
note mummification [69,70] of the underlying photoreceptor outer segments and RPE (hematoxylin and eosin, original magnification 20×).
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783biologic  processes  (Table  2).  Eight  of  the  proteins  were
classified as being integral to the cell membrane, six of which
have  roles  in  signal  transduction  and  two  of  which  are
involved  in  the  immune  response.  Two  proteins  were
classified  as  specific  to  organelle  membranes  (Golgi  and
endoplasmic reticulum). Five proteins were identified that
localize in the cytoplasm, while three others localize in the
extracellular region. Four of the proteins have association with
the post-translational modification function and two play a
role in the inflammatory response. One cytoplasmic protein,
keratin 18, is an intermediate filament of the cytoskeleton and
was classified in terms of its biologic process as having an
association with the regulation of apoptosis.
DISCUSSION
In  this  study,  we  describe  a  panel  of  candidate  protein
biomarkers  that  appear  to  be  considerably  elevated  in
response to acute laser-induced injury of the retina. We used
a global proteomics approach to analyze serum, along with a
stringent  data  filtering  method,  to  detect  and  identify  the
proteins most consistently elevated following laser treatment.
Liquid  chromatography/tandem  mass  spectrometry-
based shotgun proteomics is a highly sensitive technique to
detect alterations in the proteome of diseased tissue or body
fluid. Proteomic analysis of complex mixtures, such as serum,
can be challenging in terms of the sensitivity of detection.
Therefore,  we  employed  pre-fractionation  of  serum  by
isoelectric focusing to increase detectability of potentially low
abundant  protein  candidates.  Label-free  quantitative
proteomics  is  based  on  the  assumption  that  increased
abundance of a specific protein will lead to increased spectral
counts of its tryptic peptides identified by LC/MS/MS. The
resultant  observable  indices  include  chromatographic  ion
peak  intensity,  sequence  coverage,  peptide  number,  and
spectral count [26]. We used the spectral counting approach
for  the  relative  quantification  of  proteins  in  serum.
Comparison of the total number of MS/MS spectra detected
for a given protein (spectral counting) is a reliable and highly
reproducible method for relative quantitation. In fact, it has
been demonstrated that spectral count is the factor with the
strongest correlation (r2=0.9997) to protein abundance [27].
We used the G statistic to assess significant differences and
then applied a post-hoc Holm-Sidak adjustment of the p value
to correct for multiple testing. The G-test was found to be the
most appropriate method of statistical analysis based upon our
experimental design [24,28]. We applied additional layers of
stringency  to  the  data  filtering  process  to  minimize  false
identifications,  to  identify  proteins  that  were  significantly
upregulated  following  laser  injury,  and  to  increase  our
confidence in the final protein biomarker candidate list.
Since  the  retinal  damage  was  localized  to  the  RPE
photoreceptor complex, we expected that photoreceptor- and
RPE-specific proteins would be detected in the serum. For this
to be the case, one presumes these proteins survive the laser
assault intact, are shed from cells, and pass into the circulation
system in detectable amounts. Our inability to detect any
Figure  2.  Proteins  with  significantly
higher spectral counts at two time points
following  laser  treatment.  Counts  are
represented  as  mean  number  of
normalized  scans±SEM  for  control
(n=6) and treated samples (n=6) at 4 h
(4 h), 1 day (1 day), and 3 days (3 days)
following  either  mock  or  laser
treatment.  *p≤0.05,  **p≤0.01,
***p≤0.001, for significant differences
in  treated  samples  compared  with
corresponding  controls  at  each  time
point.
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785retina-specific proteins in serum following laser injury might
be attributed to several causes. These proteins may have been
more vulnerable to degradation either at the site of laser injury
or upon entering the systemic circulation. Also, if retina-
specific  proteins  were  indeed  present  in  serum,  their
concentrations may have been far too low for detection using
this mass spectrometry approach.
The candidate protein biomarkers identified in this study
represent  a  wide  array  of  proteins  that  were  elevated  to
significant  levels  in  the  serum  during  the  early  phases
following injury, but that appeared to rapidly return to basal
levels. These proteins may have been upregulated locally in
the  retina  at  the  site  of  injury  and  may  have  entered  the
systemic  circulation  through  a  compromised  blood-retina
barrier (BRB). Retinal laser injury could lead to induction of
pathways  for  response  to  ischemia,  inflammation,  or  cell
death  [8,9].  Events  such  as  these,  resulting  in  protein
upregulation, might explain the presence of detectable levels
in serum. Gene ontology analysis revealed four proteins with
common biologic processes that are known to participate in
immune  responses.  Two  of  these  proteins,  C-C  motif
chemokine 5 (CCL5) and Complement factor 4 (C4), are more
specifically classified as inflammatory response proteins. C-
C motif chemokine 5 is expressed in the RPE and may have
a role in the migration of inflammatory cells across the BRB
[29,30]. Increased expression of CCL5 has been associated
with autoimmune uveitis [31,32] and has been shown to be a
potential serum marker of diabetic retinopathy [33]. The idea
that  chemokine  production  at  the  BRB  may  increase  in
response to retinal injury, controlling infiltration of immune
cells,  and  may  be  detectable  at  the  systemic  level,  is  of
particular interest and requires further investigation. We also
observed that the temporal profile of the biomarker response
may correspond to both the gene expression changes shown
to occur following retinal injury [34] and the initial tissue
changes after laser injury reported by Tso et al. [5,7,35].
Photoreceptor mummification and RPE necrosis from thermal
damage,  ischemia  resulting  from  damage  to  the
choriocapillaris,  and  disruption  of  the  outer  BRB,  all
histologically observed at 1 day post-injury, coincides with
our observation of maximum protein biomarker elevation in
serum. This type of early response is similar to that described
following traumatic brain injury (TBI) or during ischemic
events in the brain, where a rapid and transient upregulation
of proteins marks the acute-phase reaction [36-38]. The most
successful surrogate marker of TBI, protein S-100B, when
measured in serum has been shown to be useful in assessing
injury severity [39] and as a reliable indicator of blood-brain
barrier disruption [40].
Four proteins in our analysis were significantly elevated
at both the 4 h and 1 day time points when compared to the
serum from controls and the protein levels returned to baseline
after 3 days. The proteins included CK18, PGK1, FUT3, and
EPHA2. At 4 h following injury, these proteins were detected
as being significantly elevated in the serum and then showed
a trend toward further elevation after 1 day, suggesting a
continuous release of proteins with changes in the biomarker
profile for up to 24 h following laser treatment. Although other
proteins that showed significant change at only one time point
may indeed be of importance, the changes seen with CK18,
PGK1, FUT3, and EPHA2 are most apparent and are therefore
discussed in detail below.
CK18 is one of the four proteins that showed a transient
significant increase in the serum following retinal laser injury.
The protein, a component of the cytoskeleton belonging to the
intermediate filament family of proteins, is expressed mainly
in  epithelial  cells  [41].  In  the  retina,  CK18  expression  is
restricted to the RPE and is the dominant cytokeratin type in
those cells [42-44]. This specificity makes CK18 an effective
marker for RPE cell identification [42]. It has been shown that
cleavage of CK18 by caspases is an early apoptotic event
[45].  Numerous  reports  suggest  that  caspase  cleaved
fragments of CK18, because they can be detected in serum,
are a useful indicator of epithelial cell death [46-48]. Our data
showed significant detection of CK18 peptides in the serum
of laser-treated animals. The peptides detected were tryptic
peptides corresponding to a region within the caspase cleaved
CK18  fragment  (data  not  shown).  We  suspect  that  acute
damage of RPE cells induced either a necrotic or apoptotic
mode of cell death and that the resulting CK18 fragments are
detectable upon release into the serum. Additional studies of
the laser dose response and other variables are needed to
determine the detection thresholds for such a biomarker in the
serum.
PGK1 is an ubiquitous glycolytic enzyme that catalyzes
the  conversion  of  1,3-diphosphoglycerate  to  3-
phosphoglycerate [49]. In the retina, PGK1 appears to be
upregulated  in  maturing  photoreceptors  [50]  and  PGK1
deficiency  has  been  implicated  in  one  case  of  retinitis
pigmentosa  [51].  It  is  likely  this  enzyme  is  abundant  in
metabolically active tissue, such as the retina, and may be the
source of the PGK1 seen in the serum after laser injury. PGK1
is  upregulated  in  response  to  hypoxia  [52,53]  and  during
hypoxia-induced apoptosis in cultured retinal neurons [54]. It
is therefore feasible that upregulation of PGK1 in the retina
might have occurred in the area surrounding the laser injury.
It remains unclear whether such an increase in expression
would contribute to elevated PGK1 serum levels within 4 h
and 1 day after laser exposure, but it is likely released as a
direct result of tissue damage in the retina.
EPHA2  belongs  to  a  subfamily  of  receptor  protein-
tyrosine kinases. Studies have shown it is expressed mainly
in the retinal ganglion cells, but also in amacrine cells and the
outer retina during development [55,56]. It plays a role in the
development of the retinotectal projection system and is also
expressed in the adult retina [55-57]. Following retinal laser
injury, altered expression is observed for both ephrin A2 in
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786the superior colliculus and EPHA5 in the retina [58]. Our
observation  of  increased  levels  of  EPHA2  in  the  serum
following  retinal  laser  injury,  affecting  mainly  the  outer
retina, is somewhat unexpected. It is possible that some injury
may  have  occurred  to  amacrine  cells  following  the  laser
injury, which was not clearly evident during our histological
assessment of one animal. Also, since EPHA2 is upregulated
in the region of growth cones, laser injury may stimulate its
production in the outer retina. It is possible that elevated levels
of EPHA2 in the inner retina diffuse through a disrupted BRB
in  response  to  injury  and  enter  the  systemic  circulation,
allowing detection in the serum. Further studies of the retinal
expression of ephrin receptor A2 and additional validation is
needed before any definite conclusions can be made regarding
this finding.
FUT3 is the enzyme that catalyzes the addition of fucose
to precursor polysaccharides in the last step of Lewis antigen
biosynthesis  [59].  The  Lewis  histo-blood  group  system
comprises a set of fucosylated glycosphingolipids that are
synthesized by exocrine epithelial cells and that circulate in
body fluids. Additionally, these glycosphingolipids function
in  embryogenesis,  tissue  differentiation,  tumor  metastasis,
inflammation, and cell adhesion [60-62]. Evidence exists for
increased  FUT3  activity  and  the  resultant  increased
abundance  of  Lewis  antigen-bearing  glycolipids  during
hepatic inflammation [63], neural differentiation [64], and in
epithelial cancer cells [60,65]. It is also known that these
fucosylated glycolipids are ligands for E-selectin receptors
[66].  Because  E-selectin  is  expressed  in  retinal  vascular
endothelial cells and has a role in recruiting inflammatory
cells  across  the  BRB  [67],  it  is  possible  that  increased
expression and activity of the fucosyltransferases might occur
at a retinal injury site. This connection between E-selectin and
fucosyltransferases could be relevant to our case of retinal
injury if RPE cells do in fact express FUT3. Although the
preferential expression of FUT3 in epithelia is known, no
sources discuss its activity in the RPE. It would therefore be
necessary to assess the presence of FUT3 in RPE and identify
an increased expression following retinal injury. The reason
for elevation of this enzyme in the sera following retinal injury
remains unclear. One could suggest that this response is either
related to early-phase inflammatory processes or is a result of
FUT3 upregulation followed by release from laser-damaged
RPE  cells.  Further  investigation  into  this  response  is
warranted.
This  study  is  unique  in  that  there  are  no  comparator
studies of a similar nature that address acute retinal injury.
Most  reported  studies  have  used  proteomic  techniques  to
investigate alterations in the retinal proteome as a result of
diabetes,  age-related  macular  degeneration,  or  glaucoma.
Some  studies  have  assessed  the  proteomes  of  intraocular
fluids,  such  as  the  aqueous  humor,  and  were  able  to
demonstrate  significant  alterations  at  the  tissue  level.
However, few studies have been able to demonstrate potential
biomarkers of ocular disease in serum and there are none, to
our knowledge, relating to acute injury. Great difficulty is
typically encountered when attempting to detect potentially
low abundance proteins in a complex biologic fluid such as
serum. Our ability to identify protein biomarker candidates
was perhaps limited by the very nature of using a shotgun
proteomics  technique.  These  intrinsic  limitations  include
threshold  of  detection,  under  sampling,  and  sample
complexity [68]. Although we employed a strategy of serial
fractionation to increase the protein identification rate, the
possibility exists that retina-specific proteins may have been
present in the serum but were missed due to any of these
limitations.  We  also  considered  whether  the  biomarker
response we observed was specific to retinal laser injury or if
a similar response could occur following laser injury of other
structures,  such  as  the  trabecular  meshwork  or  iris.
Experiments to address this question would be difficult to
design. Attempts to replicate laser injury in other tissues with
effects  that  mimic  those  seen  in  the  retina  could  be
inconsistent, especially if trying to control for laser energy
levels  and  number  of  spots.  Additionally,  laser-tissue
interactions in the retina and the observed effects are different
from those elicited in other ocular tissues. This suggests that
the response, although yet to be determined, may be different.
Despite these limitations, the technique has proven useful for
comparative global protein profiling of serum and we were
able to identify biomarker candidates that may be significantly
indicative  of  acute  retinal  injury.  Further  investigation
focusing on individual candidate proteins is necessary.
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